DanCann Pharma A/S appoints Christian Carlsen as new Board Member

Report this content

COPENHAGEN, Denmark, 29 April 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) announced yesterday the presentation of Christian Carlsen as a new Board Member at DanCann Pharma. Christian Carlsen has a background as a professional advisor in life-science and pharma and will help provide further pace and innovation to the ambitious biopharma Company's activities.

At yesterday’s general meeting of DanCann Pharma A/S, the Company's annual report was approved without remarks and there were re-elections for Carsten Trads, Per Wester, Magnus Dahlmann Østergaard and Jeppe Krog Rasmussen from the current board. Subsequently, Chairman of the Board Carsten Trads was able to welcome the new board member Christian Carlsen, who in the future will contribute with his broad business experience and extensive knowledge of the pharmaceutical industry at DanCann Pharma.

Christian Carlsen has previously worked for companies such as Bavarian Nordic A/S, Labflex A/S and Novo Nordisk Engineering A/S (NNE). At NNE Christian Carlsen led a number of strategic projects and activities, including leading an initiative to establish a corporate venture business and establishing a unit with a focus on business model innovation, venture incubation and partnerships. Christian Carlsen is also a board member of, among others, Constructa Danmark A/S, Techvolver ApS, ProSave ApS and Høyrup & Clemmensen A/S.

It is this background, as well as Christian Carlsen's experience with the development of companies, his extensive knowledge of technologies in the pharmaceutical field and his special interest in medical cannabis, which will benefit DanCann Pharma. Jeppe Krog Rasmussen, who is the Founder, Board Member and CEO of DanCann Pharma, also states quite clear the fact that he is very pleased that Christian Carlsen has agreed to make his commitment available to the Company:

“I have known Christian for some time because of our joint commitment to the medical cannabis industry and have flirted with the idea of ​​introducing Christian to DanCann Pharma's Board of Directors. However, conflicts of interest in connection with Christian's previous position have made it difficult to implement the plan, but we have now managed to get Christian on the team at DanCann Pharma - and that is a huge gain for us as a company. Christian is - for me to see - one of the most insightful people in the industry and has been part of the Danish pilot program with medical cannabis since the beginning ", Jeppe Krog Rasmussen points out and elaborates:

“Christian has headed the business unit at NNE in connection with technical, commercial and investment advice of the medical cannabis industry and has thus acted as a support for large parts of the industry on behalf of NNE as part of a large number of projects in Denmark and abroad. When it comes to know-how in our field, I find it difficult to see that we can attach a more competent resource than Christian,” he says.

Comment from Christian Carlsen, new Board Member of DanCann Pharma:
“I have followed DanCann Pharma A / S and the team from the sidelines with great interest from the very beginning in 2018, where Jeppe first introduced me to the ambitious plans for the Company. Today, the Company is at a stage where it is about to show the market that the Company can eventually develop into a significant player in the Danish and international markets. This is an exciting challenge, where I can add experience from scaling life-science companies and contribute with concrete insight and experience from the medical cannabis industry", says Christian Carlsen.

Comment from Carsten Trads, the Chairman of the Board in DanCann Pharma:

”I am happy to welcome Christian Carlsen as a new member of the Board of Directors at DanCann Pharma AS. It is our goal and strategy to become a strong and fastmoving player in the market for medical and pharmaceutical cannabis. In that process Christian offers a comprehensive set of skills and competencies. Christian Carlsen brings significant experience from organizations such as Volver Ventures, Novo Nordisk Engineering and Bavarian Nordic, and I’m convinced that Christian with his reputation, his personality and his competencies will become a valuable asset for the board and for the management of DanCann Pharma A/S”, Carsten Trads concludes.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
Website: www.dancann.com